Synageva Finishes $45M Round

Xconomy Boston — 

Synageva BioPharma, a Waltham, MA-based developer of new and generic biotech drugs, said this morning that it has raised $12 million, on top of $33 million announced in May, to complete a $45 million round of financing. The round included previous investors as well as a new investor, New Leaf Venture Partners, of New York and Menlo Park, CA. Srini Akkaraju, a managing director at New Leaf, is joining the board of directors at Synageva in connection with his firm’s investment in the company.